Industry-Supported Satellite Symposia
These symposia programs are not part of the ACEP21 educational program as planned by ACEP’s Educational Meetings Subcommittee
All times are EDT. Schedule is subject to change.
Maintaining Vigilance to Mitigate Cancer Immunotherapy-Related Toxicities in the Emergency Department: Be Aware, Stay Alert, and Change Your Practice
- GRANTORS: AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc.
- Date: Monday, October 25
- Time: 7-8 am, 6:30-7 am breakfast and registration
- Location: Grand Ballroom B, Westin Boston Seaport District
For more information and to register, please visit: www.PeerView.com/OncEm21-Live
Attending virtually? Register here to watch the live web broadcast.
Patients with cancer often present to the ED in an acutely ill state with complications from their cancer or treatments used, but a broadening use of a new class of cancer immunotherapies has changed the types of complications experienced by these patients. This spectrum of unique toxicities, termed immune-related adverse events (irAEs), is less well known, and commonly, they are overlooked, misdiagnosed, and not appropriately managed in ED settings. Standard algorithms for diagnosis and treatment no longer apply, as irAEs require a distinct approach. Are you prepared to handle the new category of oncologic emergencies you are likely to increasingly encounter in your ED?
This PeerView Live Candid Conversations and Clinical Consults hybrid event will help you get up to date and change your practice. Emergency medicine and oncology experts will join forces to provide both in-person and virtual attendees with practical, case-based guidance for timely and accurate recognition, triage, diagnosis, and management of irAEs associated with novel immunotherapies in patients with cancer who present to the ED.
Upon completion of this activity, participants should be better able to:
- Review the biologic reasons and mechanisms that drive the development of immune-related adverse effects (irAEs) during or after treatment with cancer immunotherapies
- Describe the spectrum of irAEs associated with immune checkpoint inhibitors and combinations, including those most likely to be encountered by emergency medicine (EM) professionals in the emergency department (ED)
- Implement latest recommendations for identification, assessment, diagnosis/differential diagnosis, and management of irAEs in ED settings
- Integrate team-based approaches to triage, evaluate, diagnose, and manage pertinent irAEs in the ED in collaboration with oncology professionals
Faculty: Mark M. Awad, MD, PhD and Christopher Baugh, MD, MBA
Physician Continuing Medical Education
Medical Learning Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medical Learning Institute, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is developed with our educational partner, PVI, PeerView Institute for Medical Education.
This activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc.